Tumor Necrosis Factor Receptor Blocking Activity [MoA] class drugs

20 results
  • amjevita - adalimumab - atto injection

    (Adalimumab-Atto)
    Amgen, Inc
    TNF blocker for rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and non-infectious uveitis in adults and eligible pediatric patients.
  • avsola - infliximab - axxq injection, powder, lyophilized, for solution

    (Infliximab-Axxq)
    Amgen, Inc
    Avsola is a TNF blocker for moderately to severely active Crohn's disease and ulcerative colitis (adults and children ≥6 years), rheumatoid arthritis (with methotrexate), ankylosing spondylitis, psoriatic arthritis, and chronic severe plaque psoriasis in adults.
  • cimzia - certolizumab pegol

    (Certolizumab Pegol)
    Ucb, Inc.
    CIMZIA is a TNF blocker that treats moderately to severely active Crohn's disease, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and plaque psoriasis in adults, and polyarticular juvenile idiopathic arthritis in patients 2 years and older.
  • enbrel - etanercept

    (Etanercept)
    Immunex Corporation
    Enbrel is a TNF blocker for adults with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis; and for children 2+ with polyarticular juvenile idiopathic arthritis and juvenile psoriatic arthritis, and children 4+ with plaque psoriasis.
  • hadlima - adalimumab - bwwd solution

    (Adalimumab-Bwwd)
    Organon Llc
    HADLIMA is a TNF blocker for adults and children with moderately to severely active rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and non-infectious uveitis. Also indicated for juvenile idiopathic arthritis in patients 2 years and older.